Application seeking approval of subcutaneous formulation of daratumumab for the treatment of relapsed/refractory multiple myeloma submitted to the European Medicines Agency

The application seeks approval of its use in combination with pomalidomide and dexamethasone for the treatment of patients who have received at least one prior line of therapy. It is a fixed dose formulation that can be administered over approximately 3-5 minutes under the skin.

Source:

Biospace Inc.